熱門資訊> 正文
Catalent在Novo收购之前强势结束24财年
2024-08-29 23:57
- Catalent (NYSE:CTLT) traded higher on Thursday after beating Street forecasts with its Q4 FY24 financials, months ahead of its pending buyout transaction with Novo Holdings, the parent entity of weight loss drugmaker Novo Nordisk (NVO).
- The contract drug manufacturer reiterated its plans to close the $16.5B all-cash deal by the end of the 2024 calendar year but didn’t conduct an earnings call or issue guidance, given the pending transaction.
- Its Q4 results beat Street forecasts as revenue for the quarter jumped ~23% YoY to $1.3B, and the company swung to profits with $23M in net earnings compared to $1.04B in net loss in the prior-year period.
- However, despite ~3% YoY in revenue growth, Catalent’s (CTLT) FY24 ended in the red as its net loss indicated an over-fourfold rise to $1.0B driven by ~227% YoY rise in non-cash goodwill impairment charges, which stood at $687M.
More on Catalent
- Beyond Elevidys: Unveiling The Competitive Landscape Of Duchenne's Muscular Dystrophy
- CDMO executive says Novo purchase of Catalent may help competition - CTFN
- Catalent gains after Sarepta's Elevidys gets label expansion
- Seeking Alpha’s Quant Rating on Catalent
- Historical earnings data for Catalent
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
